A PROVEN SAFETY PROFILE

106 of 111 patients had no adverse reaction with IDELVION*

Patients on IDELVION

The most common adverse reactions in clinical trials:

  • 1.8% Headache
  • 0.9% Dizziness
  • 0.9% Rash
  • 0.9% Eczema
  • 0.9% Hypersensitivity reaction
    (nausea and tachycardia)

*In five multicenter, prospective, open-label clinical trials with IDELVION, 111 previously treated patients (PTPs; exposed to an FIX-containing product for ≥100 exposure days) received at least one infusion of IDELVION as part of on-demand treatment of bleeding episodes, perioperative management of major and minor surgical, dental, or other invasive procedures, routine prophylaxis, or pharmacokinetic evaluation. Twenty-seven children were <12 years of age, 9 adolescents were 12 to <18 years of age, and 75 adults were ≥18 to ≤65 years of age. A total of 8,274 injections were administered over a median of 600 days (range: 25 to 1,288 days).

Up to 14-day dosing (FDA approved)

Dosing schedule that meets your patients’ needs

VIEW FULL DOSING INFORMATION
0 spontaneous bleeds

IDELVION is the only extended half-life Factor IX therapy to deliver a zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trials

VIEW EFFICACY DATA
X
You are now leaving the current website.

Do you want to continue?